Case Report
BibTex RIS Cite

An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient

Year 2018, Volume: 3 Issue: 1-2, 6 - 8, 04.04.2019

Tolga Şahin Ayfer Serin

Abstract

Hepatocellular carcinoma (HCC) is the fifth common cancer and the second cause of cancer-related death worldwide. Hepatitis C virus (HCV) is a common cause of chronic hepatitis, liver cirrhosis, and HCC. Recently, some new drugs have been developed named direct-acting antivirals (DAAs) for chronic HCV treatment. Direct-acting antivirals provide sustained viral response and total cure in over 80% of chronic hepatitis C patients. In this article, we present a patient with HCV genotype 1b-induced cirrhosis with giant HCC development after ledipasvir/sofosbuvir combination therapy. Although chronic hepatitis C infection can be cured with the combination of new generation DAAs, HCC pathogenesis and development risk in cirrhotic cases are still unclear. Thus, cirrhotic patients treated with DAAs should be followed-up at close intervals after treatment.

Keywords

Hepatitis C virus hepatocellular carcinoma ledipasvir sofosbuvir

References

  • 1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76. 2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. 3. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35. 4. Soliman MS, Soliman YY, Ahmad Q, Yarlagadda R. An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir. J Community Hosp Intern Med Perspect 2018;8:167-9.

Year 2018, Volume: 3 Issue: 1-2, 6 - 8, 04.04.2019

Tolga Şahin Ayfer Serin

Abstract

References

  • 1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76. 2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. 3. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet 2015;385:1124-35. 4. Soliman MS, Soliman YY, Ahmad Q, Yarlagadda R. An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir. J Community Hosp Intern Med Perspect 2018;8:167-9.
There are 1 citations in total.

Details

Primary Language English
Journal Section Olgu Sunumu
Authors

Tolga Şahin 0000-0003-1569-4941

Ayfer Serin This is me 0000-0003-4083-4280

Publication Date April 4, 2019
Published in Issue Year 2018 Volume: 3 Issue: 1-2

Cite

APA Şahin, T., & Serin, A. (2019). An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi, 3(1-2), 6-8.
AMA Şahin T, Serin A. An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi. April 2019;3(1-2):6-8.
Chicago Şahin, Tolga, and Ayfer Serin. “An Unwanted Side Effect: Giant Hepatocellular Carcinoma Development After ledipasvir/Sofosbuvir Therapy in a Chronic Hepatitis C Virus-Induced Cirrhotic Patient”. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi 3, no. 1-2 (April 2019): 6-8.
EndNote Şahin T, Serin A (April 1, 2019) An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi 3 1-2 6–8.
IEEE T. Şahin and A. Serin, “An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient”, İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi, vol. 3, no. 1-2, pp. 6–8, 2019.
ISNAD Şahin, Tolga - Serin, Ayfer. “An Unwanted Side Effect: Giant Hepatocellular Carcinoma Development After ledipasvir/Sofosbuvir Therapy in a Chronic Hepatitis C Virus-Induced Cirrhotic Patient”. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi 3/1-2 (April 2019), 6-8.
JAMA Şahin T, Serin A. An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi. 2019;3:6–8.
MLA Şahin, Tolga and Ayfer Serin. “An Unwanted Side Effect: Giant Hepatocellular Carcinoma Development After ledipasvir/Sofosbuvir Therapy in a Chronic Hepatitis C Virus-Induced Cirrhotic Patient”. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi, vol. 3, no. 1-2, 2019, pp. 6-8.
Vancouver Şahin T, Serin A. An unwanted side effect: Giant hepatocellular carcinoma development after ledipasvir/sofosbuvir therapy in a chronic hepatitis C virus-induced cirrhotic patient. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi. 2019;3(1-2):6-8.
 Download Cover Image